| Trial ID: | L0965 |
| Source ID: | NCT00240994
|
| Associated Drug: |
Alemtuzumab
|
| Title: |
Safety in Immunomodulatory Functions of Alemtuzumab (Campath) in Pediatric Kidney Transplantation Recipients
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT00240994/results
|
| Conditions: |
Kidney Failure, Chronic|Kidney Transplantation|Immunosuppression
|
| Interventions: |
DRUG: Alemtuzumab|DRUG: Tacrolimus|DRUG: Mycophenolate mofetil|DRUG: Sirolimus
|
| Outcome Measures: |
Primary: The Proportion of Participants With Graft Loss or Death Within 12 Months Post Kidney Transplantation, Graft loss is defined as the need for dialysis for more than 30 days duration, allograft nephrectomy, or the decision to withdraw immunosuppression due to graft failure., Up to one year post kidney transplantation procedure |
|
| Sponsor/Collaborators: |
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Collaborators: Cooperative Clinical Trials in Pediatric Transplantation
|
| Gender: |
ALL
|
| Age: |
CHILD, ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
35
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION
|
| Start Date: |
2005-01
|
| Completion Date: |
2009-11
|
| Results First Posted: |
2012-10-25
|
| Last Update Posted: |
2017-01-02
|
| Locations: |
University of California, San Francisco, San Francisco, California, 94143-0116, United States|Children's Hospital, Boston, Boston, Massachusetts, 02115, United States|Children's Hospital, Philadelphia, Philadelphia, Pennsylvania, 19104, United States|Children's Hospital and Regional Medical Center, Seattle, Seattle, Washington, 98105, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00240994
|
